Cited by 884Cancer-related Molecular PathwaysCancer Genomics and DiagnosticsGenetic factors in colorectal cancer

The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.

TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes

Petitjean, A, Achatz, M I W, Borresen-Dale, A L, Hainaut, P, Olivier, M·2007·Oncogene

Open this paper in CoChat — free account

Abstract

A large amount of data is available on the functional impact of missense mutations in TP53 and on mutation patterns in many different cancers. New data on mutant p53 protein function, cancer phenotype and prognosis have recently been integrated in the International Agency for Research on Cancer TP53 database (http://www-p53.iarc.fr/). Based on these data, we summarize here current knowledge on the respective roles of mutagenesis and biological selection of mutations with specific functional characteristic in shaping the patterns and phenotypes of mutations observed in human cancers. The main conclusion is that intrinsic mutagenicity rates, loss of transactivation activities, and to a lesser extent, dominant-negative activities are the main driving forces that determine TP53 mutation patterns and influence tumor phenotype. In contrast, current experimental data on the acquisition of oncogenic activities (gain of function) by p53 mutants are too scarce and heterogenous to assess whether this property has an impact on tumor development and outcome. In the case of inherited TP53 mutations causing Li-Fraumeni and related syndromes, the age at onset of some tumor types is in direct relation with the degree of loss of transactivation capacity of missense mutations. Finally, studies on large case series demonstrate that TP53 mutations are independent markers of bad prognosis in breast and several other cancers, and that the exact type and position of the mutation influences disease outcome. Further studies are needed to determine how TP53 haplotypes or loss of alleles interact with mutations to modulate their impact on cancer development and prognosis.

Integrity signals

Registry

Crossref · 10.1038/sj.onc.1210302

Cites

117 of 117 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
Sørlie, T., Perou, C. M., Tibshirani, R. J., Aas, T., Geisler, S. B., Johnsen, H., Hastie, T. J., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 11,506
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Surfing the p53 network
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · cited 2×
“191117) encodes a transcription factor which is activated in response to several forms of cellular stress and exerts multiple, antiproliferative functions (Vogelstein et al., 2000).”
Background
Instability and decay of the primary structure of DNA
Lindahl, T. (1993) · Nature · doi:10.1038/362709a0 · Cited by 5,679
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Patterns of somatic mutation in human cancer genomes
Greenman, C. D., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G. R., Davies, H. R., Teague, J. W., Butler, A. P., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,143
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,559

Show all 117 references

Research works printed but not linked: 1

Langerod A, Burdette L, Yeager M, Llaca V, Presswalla S, Gerhard DS et al. (2006a). Pattern of genetic variation in the tp53 locus indicates linkage disequilibrium extends across the flanking genes, ATP1B2 and WDR79. Hum Mutat (in press).

Sorted by citations

Items 401–500 of 883

TP53 in AML and MDS: The new (old) kid on the block
Marks, J. A., Wang, X., Fenu, E. M., Bagg, A., & Lai, C. (2023) · Blood Reviews · doi:10.1016/j.blre.2023.101055 · Cited by 20
Genotype and Haplotype Analyses of TP53 Gene in Breast Cancer Patients: Association with Risk and Clinical Outcomes
Vymetalkova, V. P., Souček, P., Kunická, T., Jirásková, K., Brynychová, V., Pardini, B., Novosadová, V., Polívková, Z., Kubáčková, K., Koževnikovová, R., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134463 · Cited by 20
Whole Genome Sequence Analysis Suggests Intratumoral Heterogeneity in Dissemination of Breast Cancer to Lymph Nodes
Blighe, K., Kenny, L. M., Patel, N. R., Guttery, D. S., Page, K., Gronau, J. H., Golshani, C., Stebbing, J., Coombes, R. C., & Shaw, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115346 · Cited by 21
Fetal colon cell line FHC exhibits tumorigenic phenotype, complex karyotype, and TP53 gene mutation
Souček, K., Gajdušková, P., Brázdová, M., Hýžďalová, M., Kočí, L., Vydra, D., Trojanec, R., Pernicová, Z., Lentvorská, L., Hajdúch, M., et al. (2010) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2009.11.009 · Cited by 21
Apoptosis-related genes induced in response to ketamine during early life stages of zebrafish
Félix, L. M., Serafim, C., Valentim, A. M., Antunes, L. M., Matos, M., & Coimbra, A. M. (2017) · Toxicology Letters · doi:10.1016/j.toxlet.2017.07.888 · Cited by 20
The p53 activator overcomes resistance to ALK inhibitors by regulating p53-target selectivity in ALK-driven neuroblastomas
Miyazaki, M., Otomo, R., Matsushima‐Hibiya, Y., Suzuki, H., Nakajima, A., Abe, N., Tomiyama, A., Ichimura, K., Matsuda, K., Watanabe, T., et al. (2018) · Cell Death Discovery · doi:10.1038/s41420-018-0059-0 · Cited by 20
Ubiquitin-Regulated Cell Proliferation and Cancer
Pérez‐Benavente, B., Fathinajafabadi, A., & Farrás, R. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-38266-7_1 · Cited by 21
Detection of Single Nucleotide Polymorphisms in p53 Mutation Hotspots and Expression of Mutant p53 in Human Cell Lines Using an Enzyme‐Linked Electrochemical Assay
Horáková, P., Šimková, E., Vychodilová, Z., Brázdová, M., & Fojta, M. (2009) · Electroanalysis · doi:10.1002/elan.200904656 · Cited by 20
PTTG and PBF Functionally Interact with p53 and Predict Overall Survival in Head and Neck Cancer
Read, M. L., Modasia, B., Fletcher, A., Thompson, R. J., Brookes, K., Rae, P. C., Nieto, H. R., Poole, V. L., Roberts, S., Campbell, M. J., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0855 · Cited by 20
18F-FDG PET-CT for Surveillance of Brazilian Patients with Li-Fraumeni Syndrome
Nogueira, S. T. D. S., Lima, E. N. P., de Nóbrega, A. F., Torres, I. D. C. G., Cavicchioli, M., Hainaut, P. L., & Achatz, M. I. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00038 · Cited by 19
Self-citation
Association between TP53 Arg72Pro polymorphism and thyroid carcinoma risk
Wang, F., Wang, P., Wang, B., Fu, Z., Yuan, Y., Yan, S.-L., Zhao, W., & Wang, Y. (2013) · Tumor Biology · doi:10.1007/s13277-013-1359-x · Cited by 19
PLCE1 polymorphisms and expression combined with serum AFP level predicts survival of HBV-related hepatocellular carcinoma patients after hepatectomy
Liao, X., Han, C., Qin, W., Liu, X., Yu, L., Zhu, G., Yu, T., Lu, S., Su, H., Liu, Z., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16346 · Cited by 19
Fischer 344-Tp53 knockout rats exhibit a high rate of bone and brain neoplasia with frequent metastasis
Hansen, S. A., Hart, M. L., Busi, S. B., Parker, T. W., Goerndt, A., Jones, K. B., Amos-Landgraf, J. M., & Bryda, E. C. (2016) · Disease Models & Mechanisms · doi:10.1242/dmm.025767 · Cited by 19
18FDG-PET/CT and molecular markers to predict response to neoadjuvant chemotherapy and outcome in HER2-negative advanced luminal breast cancers patients
de Crémoux, P., Biard, L., Poirot, B., Bertheau, P., Teixeira, L., Lehmann‐Che, J., Bouhidel, F. A., Merlet, P., Espié, M., Resche‐Rigon, M., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24674 · Cited by 19
The p53 stabilizing agent CP-31398 and multi-kinase inhibitors. Designing, synthesizing and screening of styrylquinazoline series
Mularski, J., Malarz, K., Pacholczyk, M., & Musioł, R. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.12.012 · Cited by 21
High Expression of CARM1 Inhibits Lung Cancer Progression by Targeting TP53 by Regulating CTNNB1
Hu, B., Li, X., Chen, L., & Liu, Z. (2020) · Lung · doi:10.1007/s00408-020-00324-7 · Cited by 19
Novel Implications of DNA Damage Response in Drug Resistance of Malignant Cancers Obtained from the Functional Interaction between p53 Family and RUNX2
Ozaki, T., Nakamura, M., & Shimozato, O. (2015) · Biomolecules · doi:10.3390/biom5042854 · Cited by 18
P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapse‐free survival
Assi, R. E., Gur, H. D., Loghavi, S., Konoplev, S. N., Konopleva, M. Y., Daver, N. G., Tashakori, M., Kadia, T. M., Routbort, M. J., Salem, A., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25255 · Cited by 19
Functional investigations of p53 acetylation enabled by heterobifunctional molecules
Chen, L.-Y., Singha Roy, S. J., Jadhav, A. M., Wang, W. W., Chen, P.-H., Bishop, T., Erb, M. A., & Parker, C. G. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.4c00438 · Cited by 18
Tailoring Chemotherapy for the African-Centric S47 Variant of TP53
Barnoud, T., Budina-Kolomets, A., Basu, S., Leu, J. I.-J., Good, M., Kung, C.-P., Liu, J., Liu, Q., Villanueva, J., Zhang, R., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1327 · Cited by 17
Maspin subcellular expression in wild-type and mutant TP53 gastric cancers
Gurzu, S., Jung, I., Sugimura, H., Staden, R. S., Yamada, H., Natsume, H., Iwashita, Y., Szodorai, R., & Szederjesi, J. (2020) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v12.i7.741 · Cited by 18
Non-Invasive Assessment of Hypoxia and Neovascularization with MRI for Identification of Aggressive Breast Cancer
Bennani‐Baïti, B., Pinker, K., Zimmermann, M., Helbich, T. H., Baltzer, P., Clauser, P., Kapetas, P., Bagó-Horváth, Z., & Stadlbauer, A. (2020) · Cancers · doi:10.3390/cancers12082024 · Cited by 18
The Interplay between Dysregulated Metabolism and Epigenetics in Cancer
Bassal, M. A. (2023) · Biomolecules · doi:10.3390/biom13060944 · Cited by 19
Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment
Rowdo, F. P. M., Xiao, G., Khramtsova, G. F., Nguyen, J., Martini, R. N., Stonaker, B., Boateng, R., Oppong, J. K., Adjei, E. K., Awuah, B., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216608 · Cited by 18
Mutant p53 gain of oncogenic function: in vivo evidence, mechanism of action and its clinical implications.
Adhikari, A. S., & Iwakuma, T. (2009) · PubMed · doi:10.15017/15090 · Cited by 18
p53 Status and Its Prognostic Role in Extrahepatic Bile Duct Cancer: A Meta-Analysis of Published Studies
Wang, J., Wang, X., Xie, S., Yan, Z., Li, Z., Li, Y., Wang, L., & Jiao, F. (2010) · Digestive Diseases and Sciences · doi:10.1007/s10620-010-1352-9 · Cited by 18
A Screen for Selective Killing of Cells with Chromosomal Instability Induced by a Spindle Checkpoint Defect
Shaukat, Z., Wong, H. W. S., Nicolson, S., Saint, R. B., & Gregory, S. L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047447 · Cited by 18
Detection of TP53 R249 Mutation in Iranian Patients with Pancreatic Cancer
Mohamadkhani, A., Naderi, E., Sharafkhah, M., Fazli, H. R., Moradzadeh, M., & Pourshams, A. (2013) · Journal of Oncology · doi:10.1155/2013/738915 · Cited by 18
Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression
Mota, A., Triviño, J. C., Rojo‐Sebastián, A., Martínez‐Ramírez, Á., Chiva, L. M., González-Martı́n, A., García, J. F., García‐Sanz, P., & Moreno‐Bueno, G. (2015) · BMC Cancer · doi:10.1186/s12885-015-1952-z · Cited by 18
Somatic Mutations in Prostate Cancer: Closer to Personalized Medicine
Álvarez-Cubero, M. J., Martínez-González, L. J., Robles‐Fernandez, I., Martínez‐Herrera, J. F., Garcia-Rodriguez, G., Pascual-Geler, M., Cozar, J. M., & Lorente, J. A. (2016) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-016-0248-6 · Cited by 19
Small Molecules Targeting Mutant P53: A Promising Approach for Cancer Treatment
Lopes, E. A., Gomes, S., Saraiva, L., & Santos, M. M. M. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666181116124308 · Cited by 19
Diverse and cancer type‑specific roles of the p53 R248Q gain‑of‑function mutation in cancer migration and invasiveness
Olszewski, M. B., Pruszko, M., Snaar-Jagalska, E. B., Żylicz, M., & Żylicz, M. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4723 · Cited by 18
Mdm2-P53 Interaction Inhibitor with Cisplatin Enhances Apoptosis in Colon and Prostate Cancer Cells In-Vitro
Gupta, A., Behl, T., Heer, H., Deshmukh, R. R., & Sharma, P. L. (2019) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2019.20.11.3341 · Cited by 17
Olaparib Monotherapy for BRIP1-Mutated High-Grade Serous Endometrial Cancer
Nakamura, K., Aimono, E., Tanishima, S., Imai, M., Nagatsuma, A. K., Hayashi, H., Yoshimura, Y., Nakayama, K., Kyo, S., & Nishihara, H. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00368 · Cited by 20
Genotype-phenotype correlations among TP53 carriers: Literature review and analysis of probands undergoing multi-gene panel testing and single-gene testing
Fortuño, C., Pesaran, T. F., Mester, J. L., Dolinsky, J. S., Yussuf, A., McGoldrick, K., James, P. A., & Spurdle, A. B. (2020) · Cancer Genetics · doi:10.1016/j.cancergen.2020.09.002 · Cited by 20
Identification of Genetic Mutations in Human Lung Cancer by Targeted Sequencing
Feng, H., Wang, X., Zhang, Z., Tang, C., Ye, H., Jones, L. E., Lou, F., Zhang, D., Jiang, S., Sun, H., et al. (2015) · Cancer Informatics · doi:10.4137/cin.s22941 · Cited by 19
Phosphorylation of NTRK1 at Y674/Y675 induced by TP53-dependent repression of PTPN6 expression: A potential novel prognostic marker for breast cancer
Youssef, G., Gillett, C., Agbaje, O., Crompton, T., & Montano, X. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.129 · Cited by 18
Clinical Impact of Somatic Variants in Homologous Recombination Repair-Related Genes in Ovarian High-Grade Serous Carcinoma
Choi, M. C., Hwang, S., Kim, S., Jung, S. G., Park, H., Joo, W. D., Song, S., Lee, C. M., Kim, T., Kang, H., et al. (2020) · Cancer Research and Treatment · doi:10.4143/crt.2019.207 · Cited by 18
ALDH1L1 variant rs2276724 and mRNA expression predict post-operative clinical outcomes and are associated with TP53 expression in HBV-related hepatocellular carcinoma
Zhu, G., Liao, X., Han, C., Liu, X., Yu, L., Qin, W., Lu, S., Su, H., Chen, Z., Liu, Z., et al. (2017) · Oncology Reports · doi:10.3892/or.2017.5822 · Cited by 17
Genome-Wide Small RNA Sequencing Identifies MicroRNAs Deregulated in Non-Small Cell Lung Carcinoma Harboring Gain-of-Function Mutant p53
Datta, A., Das, P. K., Dey, S., Ghuwalewala, S., Ghatak, D., Alam, S. K., Chatterjee, R., & Roychoudhury, S. (2019) · Genes · doi:10.3390/genes10110852 · Cited by 17
Integrative analysis of multi-omics data highlighted TP53 as a potential diagnostic and prognostic biomarker of survival in breast invasive carcinoma patients
Hameed, Y., & Ejaz, S. (2021) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2021.107457 · Cited by 17
Progress toward Better Treatment of Therapy-Related AML
Kotsiafti, A., Giannakas, K., Christoforou, P., & Liapis, K. (2023) · Cancers · doi:10.3390/cancers15061658 · Cited by 18
Cannflavins A and B with Anti-Ferroptosis, Anti-Glycation, and Antioxidant Activities Protect Human Keratinocytes in a Cell Death Model with Erastin and Reactive Carbonyl Species
Li, H., Deng, N., Puopolo, T., Jiang, X. L., Seeram, N. P., Liu, C., & Ma, H. (2023) · Nutrients · doi:10.3390/nu15214565 · Cited by 17
Molecular profiling of oral epithelial dysplasia and oral squamous cell carcinoma using next generation sequencing
Krishnan, R. P., Pandiar, D., Ramani, P., & Jayaraman, S. (2024) · Journal of Stomatology Oral and Maxillofacial Surgery · doi:10.1016/j.jormas.2024.102120 · Cited by 17
Uncovering functional lncRNAs by scRNA-seq with ELATUS
Goñi, E., Mas, A. M., González, J., Abad, A., Santisteban, M., Fortes, P., Huarte, M., & Hernáez, M. (2024) · Nature Communications · doi:10.1038/s41467-024-54005-7 · Cited by 17
Nutlin-3 downregulates p53 phosphorylation on serine392and induces apoptosis in hepatocellular carcinoma cells
Shi, X., Liu, J., Ren, L., Mao, N., Tan, F., Ding, N., Yang, J., & Li, M. (2014) · BMB Reports · doi:10.5483/bmbrep.2014.47.4.146 · Cited by 17
Molecular biomarkers for predicting outcomes in urothelial carcinoma of the bladder
Sapre, N., Herle, P., Anderson, P., Corcoran, N. M., & Hovens, C. M. (2014) · Pathology · doi:10.1097/pat.0000000000000110 · Cited by 17
WTp53 induction does not override MTp53 chemoresistance and radioresistance due to gain-of-function in lung cancer cells
Cuddihy, A. R., Jalali, F., Coackley, C. L., & Bristow, R. G. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0471 · Cited by 17
APC, FBXW7, KRAS, PIK3CA, and TP53 Gene Mutations in Human Colorectal Cancer Tumors Frequently Detected by Next-Generation DNA Sequencing
XD, C. Z. T. (2014) · Journal of Molecular and Genetic Medicine · doi:10.4172/1747-0862.1000145 · Cited by 18
Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS)
Garziera, M., Cecchin, E., Canzonieri, V., Sorio, R., Giorda, G., Scalone, S., Mattia, E. D., Roncato, R., Gagno, S., Poletto, E., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051510 · Cited by 17
p53 major hotspot variants are associated with poorer prognostic features in hereditary cancer patients
Fortuño, C., Pesaran, T. F., Dolinsky, J. S., Yussuf, A., McGoldrick, K., Kho, P. F., James, P. A., & Spurdle, A. B. (2019) · Cancer Genetics · doi:10.1016/j.cancergen.2019.05.002 · Cited by 20
Insight updating of the molecular hallmarks in ovarian carcinoma
Mota, A., Oltra, S. S., & Moreno‐Bueno, G. (2020) · European Journal of Cancer Supplements · doi:10.1016/j.ejcsup.2019.11.001 · Cited by 18
Radiosensitization of prostate cancer by priming the wild-type p53-dependent cellular senescence pathway
Lehmann, B. D., McCubrey, J. A., & Terrian, D. M. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.8.4544 · Cited by 17
Immunophenotypes of Glycogen Rich Clear Cell Carcinoma
Kim, S. E., Koo, J. S., & Jung, W.-H. (2012) · Yonsei Medical Journal · doi:10.3349/ymj.2012.53.6.1142 · Cited by 17
Le carcinome nasopharyngé en Afrique du Nord et dans le Sud-Est asiatique : entre similitude et différence
Ayadi, W., Khabir, A., Hadhri-Guiga, B., Fki‐Berrajah, L., Toumi, N., Siala, W., Charfi, S., Fendri, A., Makni, H., Boudawara, T. S., et al. (2010) · Bulletin du Cancer · doi:10.1684/bdc.2010.1090 · Cited by 17
Computational prediction and analysis of deleterious cancer associated missense mutations in DYNC1H1
Sucularlı, C., & Arslantas, M. (2017) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2017.04.004 · Cited by 17
The Multifaceted Role of p53 in Cancer Molecular Biology: Insights for Precision Diagnosis and Therapeutic Breakthroughs
Xu, B., Maimaitijiang, A., Nuerbiyamu, D., Su, Z., & Li, W. (2025) · Biomolecules · doi:10.3390/biom15081088 · Cited by 19
m6A‐ and immune‐related lncRNA signature confers robust predictive power for immune efficacy in lung squamous cell carcinoma
Ding, Z., Liu, Y., Huang, Q., Cheng, C., Song, L., Zhang, C., Cui, X., Wang, Y., Han, Y., & Zhang, H. (2023) · Open Research (University of Surrey) · doi:10.1002/viw.20220083 · Cited by 16
p53 terminates the regenerative fetal-like state after colitis-associated injury
Hartl, K., Bayram, Ş., Wetzel, A., Harnack, C., Lin, M., Fischer, A., Liu, L., Beccaceci, G., Mastrobuoni, G., Geisberger, S., et al. (2024) · Science Advances · doi:10.1126/sciadv.adp8783 · Cited by 16
Benzene-induced mutational pattern in the tumour suppressor gene TP53 analysed by use of a functional assay, the functional analysis of separated alleles in yeast, in human lung cells
Billet, S., Paget, V., Garçon, G., Heutte, N., André, V., Shirali, P., & Sichel, F. (2009) · Archives of Toxicology · doi:10.1007/s00204-009-0478-z · Cited by 16
Sensitization of multidrug-resistant cancer cells to Hsp90 inhibitors by NSAIDs-induced apoptotic and autophagic cell death
Moon, H., Kim, H.-B., Lee, S.-H., Jeun, S. E., Kang, C., & Kim, S. (2018) · Oncotarget · doi:10.18632/oncotarget.24130 · Cited by 16
The Role of Chromosome Deletions in Human Cancers
Chen, M., Yang, Y., Liu, Y., & Chen, C. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-0593-1_9 · Cited by 16
Efficacy and safety profile of statins in patients with cancer: a systematic review of randomised controlled trials
Thomas, J. P., Loke, Y. K., & Alexandre, L. (2020) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-02967-0 · Cited by 17
APR-246 combined with 3-deazaneplanocin A, panobinostat or temozolomide reduces clonogenicity and induces apoptosis in glioblastoma cells
de la Rosa, J., Urdiciain, A., Zelaya, M. V., Zazpe, I., Meléndez, B., REY, J. A., Idoate, M. A., & Castresana, J. S. (2021) · International Journal of Oncology · doi:10.3892/ijo.2021.5177 · Cited by 16
Prognostic Value of the TP53 Mutation Location in Metastatic Breast Cancer as Detected by Next-Generation Sequencing
Bai, H., Yu, J., Jia, S., Liu, X., Xu, L., & Li, H. (2021) · Cancer Management and Research · doi:10.2147/cmar.s298729 · Cited by 17
Prognostic features of the tumour microenvironment in oesophageal adenocarcinoma
McShane, R., Arya, S., Stewart, A. J., Caie, P. D., & Bates, M. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188598 · Cited by 16
p53 missense mutant G242A subverts natural killer cells in sheltering mouse breast cancer cells against immune rejection
Uddin, M. B., Roy, K. R., Hill, R. A., Roy, S. C., Gu, X., Li, L., Zhang, Q.-J., You, Z., & Liu, Y. (2022) · Experimental Cell Research · doi:10.1016/j.yexcr.2022.113210 · Cited by 16
Chronic low dose UV exposure and p53 mutation: Tilting the odds in early epidermal preneoplasia?
Roshan, A., & Jones, P. H. (2012) · International Journal of Radiation Biology · doi:10.3109/09553002.2012.699697 · Cited by 17
Impact of MDM2 SNP309 genotype on progression and survival of stage 4 neuroblastoma
Perfumo, C., Parodi, S., Mazzocco, K., Defferrari, R., Inga, A., Haupt, R., Fronza, G., & Tonini, G. P. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.08.018 · Cited by 16
NDRG2 promotes adriamycin sensitivity through a Bad/p53 complex at the mitochondria in breast cancer
Wei, Y., Yu, S., Zhang, Y., Zhang, Y., Zhao, H., Xiao, Z. J., Yao, L., Chen, S., & Zhang, J. (2017) · Oncotarget · doi:10.18632/oncotarget.16035 · Cited by 16
Clinicopathological Correlations of Cyclooxygenase-2, MDM2, and p53 Expressions in Surgically Resectable Pancreatic Invasive Ductal Adenocarcinoma
Hermanová, M., Karásek, P., Nenutil, R., Kýr, M., Tomášek, J., Baltasova, I., & Dítě, P. (2009) · Pancreas · doi:10.1097/mpa.0b013e31819fef8b · Cited by 16
The associations of sequence variants in DNA-repair and cell-cycle genes with cancer risk: genotype–phenotype correlations
Hall, J. A., Marcel, V., Bolin, C. M., Fernet, M., Tartier, L., Vaslin, L., & Hainaut, P. L. (2009) · Biochemical Society Transactions · doi:10.1042/bst0370527 · Cited by 16
Self-citation
TP53 Cancerous Mutations Exhibit Selection for Translation Efficiency
Waldman, Y. Y., Tuller, T., Sharan, R., & Ruppin, E. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1653 · Cited by 16
Dysregulation of CDK Inhibitors and p53 in HPV-negative Endocervical Adenocarcinoma
Omori, M., Hashi, A., Kondo, T., Katoh, R., & Hirata, S. (2015) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000121 · Cited by 16
Mutant p53 protein accumulation is selectively targetable by proximity-inducing drugs
Sadagopan, A., Carson, M., Zamurs, E. J., Garaffo, N., Chang, H.-J., Schreiber, S. L., Meyerson, M. M., & Gibson, W. J. (2025) · Nature Chemical Biology · doi:10.1038/s41589-025-02051-7 · Cited by 26
TP53-Activated lncRNA GHRLOS Regulates Cell Proliferation, Invasion, and Apoptosis of Non-Small Cell Lung Cancer by Modulating the miR-346/APC Axis
Ren, K., Sun, J., Liu, L., Yang, Y.-P., Li, H., Wang, Z., Deng, J., Hou, M., Qiu, J., & Zhao, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.676202 · Cited by 14
Multi-omics consensus portfolio to refine the classification of lung adenocarcinoma with prognostic stratification, tumor microenvironment, and unique sensitivity to first-line therapies
Zou, Y.-M., Cao, C., Wang, Y.-L., Zhou, Y.-L., Yao, S., Zhang, L.-L., Zheng, K.-P., Zhang, H., Qin, W., Qin, K., et al. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-775 · Cited by 11
The role of p53 and ki67 in predicting clinical outcome in breast cancer patients
Lalkota, B. P., Srinivasa, B. J., Swamy, M. S. S., Hazarika, D., Jeet, B., Jyothi, K., Ghosh, M., Sayeed, S., Nasiruddin, M., & Naik, R. (2023) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_1830_20 · Cited by 15
Abnormal p53 Immunohistochemical Patterns Are Associated with Regional Lymph Node Metastasis in Oral Cavity Squamous Cell Carcinoma at Time of Surgery
Lin, T. Y.-Y., Liu, K. Y. P., Novack, R., Mattu, P., Ng, T. L., Hoang, L. N., Prisman, E., Poh, C. F.-Y., & Ko, Y. C. K. (2024) · Modern Pathology · doi:10.1016/j.modpat.2024.100614 · Cited by 15
Gain-of-function p53 mutant with 21-bp deletion confers susceptibility to multidrug resistance in MCF-7 cells
Shang-Hsun, T., Hou, M.-H., Hsu, L., Chen, T.-M., & Chen, Y. (2015) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2015.2406 · Cited by 15
Coexistent Loss of the Expressions of BRCA1 and p53 Predicts Poor Prognosis in Triple-Negative Breast Cancer
Kim, M. C., Choi, J. E., Lee, S. J., & Bae, Y. K. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5307-z · Cited by 15
TP53 codon 72 polymorphism and breast cancer risk in Bangladeshi population
Hossain, A., Murshid, G. M., Zilani, M. N. H., Islam, F., Sultana, R., Sultana, T., Hossain, M. G., & Rahman, M. M. (2016) · Breast Cancer · doi:10.1007/s12282-016-0740-1 · Cited by 17
Association of the MDM2 SNP285 and SNP309 Genetic Variants with the Risk, Age at Onset and Prognosis of Breast Cancer in Central European Women: A Hospital-Based Case-Control Study
Miedl, H., Lebhard, J., Ehart, L., & Schreiber, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030509 · Cited by 14
Breast Cancer Adjuvant Radiotherapy in BRCA1/2, TP53, ATM Genes Mutations: Are There Solved Issues?
Lazzari, G., Buono, G., Zannino, B., & Silvano, G. (2021) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s306075 · Cited by 15
PSME4 Activates mTOR Signaling and Promotes the Malignant Progression of Hepatocellular Carcinoma
Ge, S., Huang, H., Huang, W., Ji, R., Chen, J., Wu, S., Wang, L., Huang, T., Sheng, Y., Yan, H., et al. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s344360 · Cited by 15
Meta‐analysis of the association between P53 codon 72 polymorphisms and gastric cancer
Zhang, Q., Ma, Y., Wang, H., Shao, C., Zhang, J., & Ye, Z. (2012) · Journal of Surgical Oncology · doi:10.1002/jso.23233 · Cited by 15
Prognostic significance of survivin, β-catenin and p53 expression in urothelial carcinoma
Şenol, S., Yıldırım, A., Ceyran, B., Uruç, F., Zemheri, E. I., Özkanlı, Ş., Akalın, İ., Ulus, I., Çaşkurlu, T., & Aydin, A. (2015) · Biomolecules and Biomedicine · doi:10.17305/bjbms.2015.556 · Cited by 15
Characterizing mutation-treatment effects using clinico-genomics data of 78,287 patients with 20 types of cancers
Liu, R., Rizzo, S., Wang, L. E., Chaudhary, N., Maund, S. L., Garmhausen, M. R., McGough, S. F., Copping, R., & Zou, J. (2024) · Nature Communications · doi:10.1038/s41467-024-55251-5 · Cited by 14
Streptavidin-enhanced assay for sensitive and specific detection of single nucleotide polymorphism in TP53
Šípová, H., Špringer, T., & Homola, J. (2010) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-010-3863-9 · Cited by 14
Proteasome inhibition prevents cell death induced by the chemotherapeutic agent cisplatin downstream of DNA damage
Costa, A. R., Machado, N., Rego, A., Sousa, M. J., Côrte‐Real, M., & Chaves, S. R. (2018) · DNA repair · doi:10.1016/j.dnarep.2018.10.006 · Cited by 14
The landscape of gene mutations and clinical significance of tumor mutation burden in patients with soft tissue sarcoma who underwent surgical resection and received conventional adjuvant therapy
Xu, L., Zhao, Z., Xu, S., Zhang, X., Liu, T., Jing, C., Zhang, S., & Yu, S. (2020) · The International Journal of Biological Markers · doi:10.1177/1724600820925095 · Cited by 14
Breast cancer patients with hypermethylation in the promoter of BRCA1 gene exhibit favorable clinical status
Krasteva, M. E., Bozhanov, S. S., Antov, G., Gospodinova, Z. I., & Angelova, S. G. (2012) · Neoplasma · doi:10.4149/neo_2012_011 · Cited by 14
P53-dependent suppression of the human calcyclin gene (S100A6): the role of Sp1 and of NFkappaB.
Króliczak, W., Pietrzak, M., & Puzianowska‐Kuźnicka, M. (2008) · Acta Biochimica Polonica · doi:10.18388/abp.2008_3062 · Cited by 14
Application of bifurcation theory and siRNA-based control signal to restore the proper response of cancer cells to DNA damage
Kozłowska, E., & Puszyński, K. (2016) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2016.08.017 · Cited by 14
Investigation of RIP140 and LCoR as independent markers for poor prognosis in cervical cancer
Vattai, A., Cavaillès, V., Doisneau-Sixou, S. F., Beyer, S., Kühn, C., Peryanova, M., Heidegger, H. H., Hermelink, K., Mayr, D. C., Mahner, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22187 · Cited by 14
Bioinformatics and Network Pharmacology of the First Crystal Structured Clerodin: Anticancer and Antioxidant Potential against Human Breast Carcinoma Cell
Pakrashy, S., Mandal, P. K., Goswami, J. N., Dey, S. K., Choudhury, S. M., Bhattacharya, B., Emmerling, F., Alasmary, F. A., & Dolai, M. (2022) · ACS Omega · doi:10.1021/acsomega.2c07173 · Cited by 15
Exploring the Role of Globular Domain Locations on an Intrinsically Disordered Region of p53: A Molecular Dynamics Investigation
Bakker, M. J., Sørensen, H. V., & Skepö, M. (2024) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.3c00971 · Cited by 13
Enhancer regulatory networks globally connect non-coding breast cancer loci to cancer genes
Wang, Y., Armendariz, D. A., Wang, L., Zhao, H., Xie, S., & Hon, G. C. (2025) · Genome biology · doi:10.1186/s13059-025-03474-0 · Cited by 13
Retention of the In Vitro Radiosensitizing Potential of Gemcitabine Under Anoxic Conditions, in p53 Wild-Type and p53-Deficient Non–Small-Cell Lung Carcinoma Cells
Wouters, A., Pauwels, B., Lambrechts, H. A. J., Pattyn, G. G. O., Ides, J., Baay, M. F. D., Meijnders, P., Peeters, M., Vermorken, J. B., & Lardon, F. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.12.051 · Cited by 13
Yield of p53 expression in esophageal squamous cell cancer and its relationship with survival
Gupta, S., Sankalecha, T., Gaikwad, N., Shirole, N. U., & Kothari, H. G. (2017) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_56_17 · Cited by 13

Authors: Petitjean, A., Achatz, M. I. W., Borresen-Dale, A. L., Hainaut, P., & Olivier, M.
Affiliations: Centre international de recherche sur le cancer (FR)
Corresponding author: Hainaut, P
ORCID: Petitjean, A
Achatz, M I W
Hainaut, P
Olivier, M
Venue: Oncogene
Publisher: Springer Science and Business Media LLC
Published: 2007-04-02
Volume: 26
Issue: 15
Pages: 2157-2165
ISSN: 0950-9232 (ISSN-L)
1476-5594
DOI: 10.1038/sj.onc.1210302
OpenAlex: W2042484101
Cited by: 884
References: 117
Citations by year: 2026: 16 · 2025: 29 · 2024: 29 · 2023: 50 · 2022: 55 · 2021: 52 · 2020: 50 · 2019: 53 · 2018: 60 · 2017: 46 · 2016: 57 · 2015: 52 · 2014: 53 · 2013: 43 · 2012: 48
FWCI: 5.08
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Oncogene (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords: TP53 mutation, missense mutations, dominant-negative p53, gain-of-function, mutagenesis, tumor phenotype, cancer prognosis, Li-Fraumeni syndrome, loss of heterozygosity, breast cancer
MeSH terms: Genetic Markers, Humans, Mutation, Neoplasms, Polymorphism, Genetic, Prognosis, Biomarkers, Tumor, Tumor Suppressor Protein p53, Mutagenesis, Li-Fraumeni Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks